AKL RESEARCH & DEVELOPMENT LIMITED
Company number 08699350 · Monitor this company
Executive summary
AKL Therapeutics is a clinical-stage biotech at a critical inflection point, having advanced to Phase 2b trials but facing a severe liquidity crisis with only £11K in cash at year-end 2025. The company's primary strategic value lies in its clinical asset and R&D tax credit position, but immediate capital injection or a licensing partnership is essential for survival. Success depends on converting Phase 2b progress into either compelling clinical data or a pharma partnership before existing capital is fully exhausted.
Shareholders' funds
-£14,445,721
Balance sheet as at 2025-12-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2013-09-20
- Employees
- 5 (2025 accounts)
- Registered office
- The Lexicon Second Floor, Mount Street, Manchester, England, M2 5NT
- Postcode
- M2 5NT
- Capital
- 396 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2025-12-31
- Next due by
- 2027-09-30
- Financial year end
- 31 December
Confirmation statement
- Last statement dated
- 2025-12-04
- Next due by
- 2026-12-18
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 5 current · 1 resigned
Group structure 1 subsidiary
From persons-with-significant-control filings on the public register.
Previous registered addresses 3
| Address | Changed on |
|---|---|
| BLACKFRAIRS HOUSE WHITE AND COMPANY, 6TH FLOOR, BLACKFRAIRS HOUSE, PARSONAGE, MANCHESTER, M3 2JA, ENGLAND | 2019-06-27 |
| UNITS 4-5 WONASTOW ROAD INDUSTRIAL ESTATE WEST, MONMOUTH, NP25 5JA | 2015-06-22 |
| THE DIRECTOR GENERAL'S HOUSE 15 ROCKSTONE PLACE, SOUTHAMPTON, HAMPSHIRE, SO15 2EP | 2014-09-12 |
Among its peers
Among the oldest 25%
of 76 similar companies in M, trading since 2013
Competitors Manchester
This company ranks 46 among research and experimental development on biotechnology in Manchester.
The class of 2013
32%
of the 311 companies in this sector incorporated in 2013 are still active today; 64% have since been dissolved.
A fact about the year, not a forecast for this company.